Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer

NCT02234596 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02234596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02234596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2014
Completion date
April 22, 2020
Enrollment
34 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

esophagogastric adenocarcinoma